文献速递心胸血管麻醉小儿麻醉

活化四因子凝血酶原复合物作为新生儿心脏手术止血辅助:倾向评分匹配队列研究

Activated 4-Factor Prothrombin Complex Concentrate as a Hemostatic Adjunct for Neonatal Cardiac Surgery: A Propensity Score-Matched Cohort Study.
PubMed 文献 · Anesth Analg · 2022-12-02

BACKGROUND: Prothrombin complex concentrates are an emerging "off-label" therapy to augment hemostasis after cardiopulmonary bypass (CPB), but data supporting their use for neonatal cardiac surgery are limited.…

要点

  • a4FPCC可减少新生儿心脏术后体外循环后输血总量。
  • a4FPCC未增加7天和30天术后血栓栓塞发生率。
  • a4FPCC组ICU和住院时间显著延长,需权衡获益。

核心结论

  • a4FPCC作为新生儿心脏手术体外循环后难治性出血的止血辅助,与输血总量减少相关,且不增加术后7天或30天血栓栓塞率。
  • 研究结果提示a4FPCC可考虑纳入新生儿心脏手术难治性出血的止血路径。

研究设计与样本

  • 共165例纳入最终分析,对照组86例,a4FPCC组79例;倾向评分匹配后每组各43例。

主要发现

  • 7天和30天术后血栓栓塞率、术后胸管引流量、拔管时间、术后急性肾损伤发生率及30天死亡率组间无统计学显著差异。

临床怎么用

  • 对于新生儿心脏手术体外循环后难治性出血,可考虑将a4FPCC作为止血辅助的一部分。
  • 使用a4FPCC时需关注ICU和住院时间可能延长的风险。

局限性

  • 回顾性研究设计。
  • 单中心数据。
  • 样本量有限(匹配后每组43例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prothrombin complex concentrates are an emerging "off-label" therapy to augment hemostasis after cardiopulmonary bypass (CPB), but data supporting their use for neonatal cardiac surgery are limited. METHODS: We retrospectively reviewed neonates undergoing open heart surgery with first-time sternotomy between May 2014 and December 2018 from a hospital electronic health record database. Neonates who received activated 4-factor prothrombin complex concentrate (a4FPCC) after CPB were propensity score matched (PSM) to neonates who did not receive a4FPCC (control group). The primary efficacy outcome was total volume (mL/kg) of blood products transfused after CPB, including the first 24 hours on the cardiovascular intensive care unit (CVICU). The primary safety outcome was the incidence of 7- and 30-day postoperative thromboembolism. Secondary outcomes included 24 hours postoperative chest tube output, time to extubation, duration of CVICU stay, duration of hospital stay, 30-day mortality, and incidence of acute kidney injury on postoperative day 3. We used linear regression modeling on PSM data for the primary efficacy outcome. For the primary safety outcome, we tested for differences using McNemar test on PSM data. For secondary outcomes, we used linear regression, Fisher exact test, or survival analyses as appropriate, with false discovery rate-adjusted P values. RESULTS: A total of 165 neonates were included in the final data analysis: 86 in the control group and 79 in the a4FPCC group. After PSM, there were 43 patients in the control group and 43 in the a4FPCC group. We found a statistically significant difference in mean total blood products transfused for the a4FPCC group (47.5 mL/kg) compared with the control group (63.7 mL/kg) for PSM patients (adjusted difference, 15.3; 95% CI, 29.4-1.3; P = .032). We did not find a statistically significant difference in 7- or 30-day thromboembolic rate, postoperative chest tube output, time to extubation, incidence of postoperative acute kidney injury (AKI), or 30-day mortality between the groups. The a4FPCC group had a significantly longer length of intensive care unit stay (32.9 vs 13.3 days; adjusted P = .049) and hospital stay (44.6 vs 24.1 days; adjusted P = .049) compared with the control group. CONCLUSIONS: We found that the use of a4FPCC as a hemostatic adjunct for post-CPB bleeding in neonatal cardiac surgery was associated with a decrease in mean total blood products transfused after CPB without an increased rate of 7- or 30-day postoperative thromboembolism. Our findings suggest that a4FPCCs can be considered as part of a hemostasis pathway for refractory bleeding in neonatal cardiac surgery.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Navaratnam M, Mendoza JM, Zhang S, et al. Activated 4-Factor Prothrombin Complex Concentrate as a Hemostatic Adjunct for Neonatal Cardiac Surgery: A Propensity Score-Matched Cohort Study. Anesth Analg. 2022. PMID: 36729967. doi:10.1213/ANE.0000000000006294

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。